Evidence map›Paper›PMID 36376510›Full record

ArticleNature cancer2022

Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.

Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Dafne Franz Demane, Mansi Shah, Eyal David, Chamutal Borenstein, Oren Barboy and 4 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ido Yofe *Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Tomer Landsberger *Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Adam Yalin *Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Isabelle SolomonCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Cristobal CostoyaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Dafne Franz DemaneCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Mansi ShahCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Eyal DavidDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Chamutal BorensteinDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Oren BarboyDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Ignacio MatosCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Karl S PeggsCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Sergio A QuezadaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9763-1700
Ido AmitDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. ido.amit@weizmann.ac.il.ORCID http://orcid.org/0000-0003-2968-877X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36376510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.